Kyowa Hakko Kirin, Ultragenyx To Develop Treatment For X-linked Hypophosphatemia

Kyowa Hakko Kirin is committed to expansion, and the deal with Ultragenyx for a first-in-class therapy of a rare bone disorder is small but establishes a clinical trial foothold overseas

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia